Nanexa Shares Surge as Novo Nordisk Licenses Drug Technology for Up to €1.165 Billion

Key Facts

Shares of Sweden's Nanexa surged on September 25, 2026, after the company announced an exclusive global licence and collaboration with Novo Nordisk on September 24 carrying potential payments of up to €1.165 billion. Reuters reported the stock was up about 122% at 0723 GMT in early Friday trading. The agreement gives Novo Nordisk rights to use Nanexa's PharmaShell platform to develop specified long-acting injectable medicines, with payments subject to different conditions and milestones. The announcement therefore changes Nanexa's commercial prospects while setting a maximum value that was not earned at signing. It was released after the Swedish market closed on Thursday, ahead of the Friday move reported by Reuters.

The potential €1.165 billion comprises an initial payment, development and regulatory milestones, and later sales milestones. Nanexa said the initial payment together with development and regulatory milestones could total €615 million, without disclosing the signing payment separately. The balance of the stated ceiling depends on future sales thresholds, putting it further from receipt than the initial consideration. Nanexa is also eligible for low-single-digit royalties on global net sales of products developed under the agreement. For valuation purposes, investors must distinguish early cash from conditional milestones and from royalties that require a product to reach the market.

PharmaShell applies an extremely thin coating to drug particles using atomic layer deposition, designed to control how quickly an active ingredient is released after injection. Its commercial proposition is a different delivery method for medicines under development rather than a new medicine in itself. The companies target formulations administered monthly or quarterly, which could reduce the number of injections needed for continuing treatment. Achieving that schedule in a marketed product still depends on successful development and the necessary approvals. The path from technical promise to revenue therefore runs through the results of individual programmes, rather than the signature on the licence alone.

The licence covers up to 5 development programmes for peptide medicines targeting obesity, type 2 diabetes and other cardiometabolic conditions. Novo Nordisk will lead worldwide development and commercialisation of covered products, while Nanexa supplies access to its platform for those programmes. That division explains how Nanexa could receive milestone payments as work progresses before any final product sales emerge. It also means recurring royalty income depends on the partner bringing a covered medicine to market and selling it, rather than simply holding worldwide rights. The announcement does not say every programme will yield an approved medicine or that the maximum payment will necessarily be made.

The relationship predates this licence: in 2022, Nanexa announced an evaluation and exclusivity agreement to test PharmaShell with Novo Nordisk products. That arrangement involved about SEK 46.1 million in agreement payments alongside a directed share issue to the partner worth SEK 17.2 million. It was structured around evaluation and joint work, whereas the new agreement establishes a global licence and defined development programmes. This sequence helps explain investor interest because a disclosed testing relationship has advanced into a commercial framework with potential payment streams. The earlier evaluation payments nevertheless differ in character and timing from the new licence's conditional ceiling.

Nanexa also announced a licence and option agreement with Moderna in 2025 covering other applications of PharmaShell. The Novo Nordisk agreement thus sits within a business model that develops the platform with partners alongside Nanexa's own projects. More partnerships can widen the opportunities to apply the technology, but success in one programme cannot automatically be carried over to another. Investors consequently need to follow whether this collaboration meets its development milestones, rather than count the number of pharmaceutical names associated with the platform. Each partnership's value depends on its own terms and on the scientific and regulatory progress of the products it covers.

The latest results published before the announcement show Nanexa's scale beside the new agreement's maximum value. In the second quarter of 2026, revenue was SEK 1.654 million versus SEK 2.705 million a year earlier, while the operating loss widened to SEK 13.882 million from SEK 5.237 million. Cash and cash equivalents at quarter-end were SEK 52.557 million, compared with SEK 40.263 million at the comparable year-earlier date. Those figures make any signing payment potentially important to funding ongoing work, although its separate amount was not disclosed. They also show why the agreement's entire ceiling cannot be treated as quarterly revenue or as cash already available to the company.

Before the licensing announcement, Nanexa and Forge Nano said on September 22, 2026, that they would jointly develop scalable manufacturing capabilities for PharmaShell-based medicines. Their work targets atomic layer deposition equipment for clinical development and potentially for future commercial production. This addresses a separate execution risk: showing that a formulation works is insufficient if it cannot be made consistently at an appropriate scale. Manufacturing capability could support several programmes, but the equipment and processes themselves must be developed and tested before they underpin commercial sales. The manufacturing agreement supports the platform's development; it does not establish that the Novo Nordisk programmes have reached commercialisation.

For a Nanexa shareholder, the licence increases the possibility of future cash from contractual milestones and royalties while leaving their amount and timing uncertain. A prospective buyer may read the early rally as a repricing of a larger commercial opportunity, but must weigh the probability of each payment tranche. An investor expecting the shares to fall is instead focused on the possible gap between the headline ceiling and what Nanexa ultimately collects. Development results, regulatory decisions and eventual sales are the variables that determine which reading proves closer to reality. A single session's share move cannot establish the revenue the company will record in subsequent years.

Nanexa scheduled management commentary on the agreement for September 25, the nearest announced opportunity for investors to hear more about its terms. Progress by specific programmes towards payment-bearing development and regulatory milestones would strengthen the positive reading, followed by products eligible for sales royalties. Delays or failed programmes could instead weaken expectations of collecting the maximum amount even if the licence remains in force. Subsequent disclosures about the timing of the initial payment and any milestones earned will matter because they separate the contract's potential value from cash entering Nanexa. Until those developments become clear, the announced figure remains a ceiling on a multistage opportunity rather than a completed financial result.